We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 06, 2020

Vismodegib Combined With Gemcitabine and Nab-Paclitaxel in Untreated Metastatic Pancreatic Adenocarcinoma

British Journal of Cancer


Additional Info

British Journal of Cancer
Phase 2 Study of Vismodegib, a Hedgehog Inhibitor, Combined With Gemcitabine and Nab-Paclitaxel in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
Br. J. Cancer 2019 Dec 20;[EPub Ahead of Print], A De Jesus-Acosta, EA Sugar, PJ O'Dwyer, RK Ramanathan, DD Von Hoff, Z Rasheed, L Zheng, A Begum, R Anders, A Maitra, F McAllister, NV Rajeshkumar, S Yabuuchi, RF de Wilde, B Batukbhai, I Sahin, DA Laheru

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading